Abstract
As antiviral therapy for HIV infection has evolved, morbidity and mortality patterns in HIV-infected patients have shifted from complications of AIDS to complications of liver disease, most notably from hepatitis C virus (HCV) infection. Abundant data have demonstrated the efficacy of pegylated interferon in HCV-infected patients who are not coinfected with HIV, but few studies exist on treatment of coinfected patients. Two large trials evaluated pegylated interferon alfa-2a plus ribavirin for treatment of chronic HCV infection in patients with well-compensated HIV disease, but not necessarily negative HIV PCR levels. In the first trial, 860 coinfected patients …
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
